for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Adamis Pharmaceuticals Corp

admp.o

Latest Trade

0.60USD

Change

0.01(+0.87%)

Volume

473,595

Today's Range

0.60

 - 

0.62

52 Week Range

0.55

 - 

1.74

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Adamis Pharmaceuticals Announces Third Quarter 2021 Financial Results And Provides Corporate Update

Adamis Pharmaceuticals Corp <ADMP.O>::ADAMIS PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.ADAMIS PHARMACEUTICALS CORP - UNDER OUR NEW COMMERCIAL PARTNER, WE HAVE SEEN SIGNIFICANT SALES GROWTH FOR SYMJEPI.ADAMIS PHARMACEUTICALS CORP - NOW ENGAGED IN A PROCESS OF SELLING OR OTHERWISE DISPOSING OF REMAINING ASSETS OF US COMPOUNDING BUSINESS.

Adamis Receives FDA Approval For ZIMHI

Oct 18 (Reuters) - Adamis Pharmaceuticals Corp <ADMP.O>::ADAMIS RECEIVES FDA APPROVAL FOR ZIMHI.ADAMIS PHARMACEUTICALS - FDA HAS APPROVED ADAMIS' ZIMHI (NALOXONE HCL INJECTION, USP) 5 MG/0.5 ML PRODUCT.

Adamis Announces Appointment Of David Benedicto As Chief Financial Officer And Other Events

Aug 24 (Reuters) - Adamis Pharmaceuticals Corp <ADMP.O>::ADAMIS ANNOUNCES APPOINTMENT OF DAVID C. BENEDICTO AS CHIEF FINANCIAL OFFICER AND OTHER EVENTS.ADAMIS PHARMACEUTICALS CORP - DAVID BENEDICTO WILL SUCCEED ROBERT O. HOPKINS AS CFO EFFECTIVE IMMEDIATELY.

Adamis Reports Agreement To Sell Portion Of US Compounding Business

Aug 4 (Reuters) - Adamis Pharmaceuticals Corp <ADMP.O>::PRESS RELEASE - ADAMIS ANNOUNCES AGREEMENT TO SELL PORTION OF US COMPOUNDING BUSINESS.ADAMIS PHARMACEUTICALS CORP - DEAL FOR ESTIMATED TO BE UP TO $15 MILLION.

Adamis Pharmaceuticals Resubmits Zimhi New Drug Application To FDA For The Treatment Of Opioid Overdose

May 17 (Reuters) - Adamis Pharmaceuticals Corp <ADMP.O>::ADAMIS PHARMACEUTICALS RESUBMITS ZIMHI NEW DRUG APPLICATION TO FDA FOR THE TREATMENT OF OPIOID OVERDOSE.

Adamis Pharmaceuticals Provides An Update On Zimhi™

April 12 (Reuters) - Adamis Pharmaceuticals Corp <ADMP.O>::ADAMIS PHARMACEUTICALS PROVIDES AN UPDATE ON ZIMHI™.ADAMIS PHARMACEUTICALS CORP - PLANS TO RESUBMIT NDA FOR ZIMHI TO FDA WITHIN NEXT 45 DAYS.

Adamis Announces Pricing Of Public Offering Of Common Stock

Jan 29 (Reuters) - Adamis Pharmaceuticals Corp <ADMP.O>::ADAMIS PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 40.5 MILLION COMMON SHARES PRICED AT $1.11PER SHARE.

Adamis Pharmaceuticals Announces Proposed Public Offering Of Common Stock

Jan 28 (Reuters) - Adamis Pharmaceuticals Corp <ADMP.O>::ADAMIS PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.

Adamis Pharmaceuticals Announces IND Submission To FDA For Tempol For The Treatment Of COVID-19

Jan 20 (Reuters) - Adamis Pharmaceuticals Corp <ADMP.O>::ADAMIS PHARMACEUTICALS ANNOUNCES IND SUBMISSION TO FDA FOR TEMPOL FOR THE TREATMENT OF COVID-19.ADAMIS PHARMACEUTICALS CORP - PLANS TO SEEK GOVERNMENT AND/OR NON-GOVERNMENT FUNDING TO STUDY TREATMENT AND PREVENTION OF COVID-19 WITH TEMPOL.ADAMIS PHARMACEUTICALS - TEMPOL HAS DEMONSTRATED BOTH POTENT ANTI-INFLAMMATORY, ANTICOAGULANT, AND ANTIOXIDANT ACTIVITY.

Adamis Pharma Describes Planned Response to ZIMHI Complete Response Letter

Dec 1 (Reuters) - Adamis Pharmaceuticals Corp <ADMP.O>::ADAMIS PHARMACEUTICALS DESCRIBES PLANNED RESPONSE TO ZIMHI COMPLETE RESPONSE LETTER.ADAMIS PHARMACEUTICALS CORP - ALL OF COMPANY'S RESPONSES TO DEFICIENCIES WILL BE SUBMITTED BEFORE YEAR END.ADAMIS PHARMACEUTICALS CORP - IF MATTER CANNOT BE RESOLVED WITH FDA DIVISION THAT SENT CRL, ADAMIS INTENDS TO APPEAL MATTER.ADAMIS - INTENDS TO ADDRESS ALL DEFICIENCIES RAISED IN CRL AND REQUEST THAT FDA APPROVE NDA FOR ZIMHI HIGH DOSE NALOXONE INJECTION PRODUCT.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up